Key Points
Johnson & Johnson delivered a “beat and raise” quarter.
Results were bolstered by the new acquisition of Intra-Cellular, marking J&J’s re-entry into the neuroscience field.
The stock is still not expensive even after today’s surge.
10 stocks we like better than Johnson & Johnson ›
Shares of Johnson & Johnson (NYSE: JNJ) rallied 6.1% on Wednesday as of 1:18 p.m. ET.
The pharmaceutical and medical equipment giant reported earnings today, which not only beat expectations, but also saw management lifting full-year guidance. As such, the stock continued to brush off tariff-related fears from the first half of the year.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Second-quarter highlights include lower-than-expected tariffs and contributions from Caplyta
In the second quarter, Johnson & Johnson grew revenue 5.8% to $23.7 billion, beating expectations. While adjusted (non-GAAP) earnings per share of $2.77 declined by 1.8% relative to the prior year, that was also ahead of analysts’ expectations.
The decline in earnings had to do with Johnson & Johnson’s cost of goods sold, which included some acquisition-related amortization stemming from the company’s $14.6 billion acquisition of neuroscience-oriented Intra-Cellular Therapies, which closed on April 2. Interest expense also increased from new debt used for the acquisition. Management also noted that it expects a $200 million impact from tariffs this year, though that was down from $400 million in April before U.S.-China tariffs were ratcheted back down on May 12.
Still, Intra-Cellular helped the company’s Neuroscience unit grow 14.4% year over year in constant currency, which was the second-fastest segment behind oncology, which grew a solid 22.3%.
Management also upped its guidance for the year and now projects $93.2 billion to $93.6 billion in revenue, and $10.80 to $10.90 in adjusted earnings per share (EPS), relative to last quarter’s guidance of $91 billion to $91.8 billion and $10.50 to $10.70, respectively.
Image source: Getty Images.
JNJ remains as blue chip as ever
Johnson & Johnson’s solid results cement it as the premier blue chip pharmaceutical and medtech company in dividend-oriented portfolios. Moreover, the stock is still inexpensive, even after today, at just 15 times this year’s new earnings guidance, with a dividend of 3.4%.
Thus, the stock remains a solid buy or hold for income-oriented, conservative investors.
Should you invest $1,000 in Johnson & Johnson right now?
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $679,653!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,046,308!*
Now, it’s worth noting Stock Advisor’s total average return is 1,060% — a market-crushing outperformance compared to 179% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 15, 2025
Billy Duberstein and/or his clients have no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
